Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Changes in the urinary proteome post-operatively in renal cancer patients - a reflection of tumour or kidney removal?

Sim SH, Cairns DA, Perkins DN, Peng J, Stanley AJ, Thompson D, Lewington A, Selby PJ, Banks RE.

Proteomics Clin Appl. 2009 Sep;3(9):1112-22. doi: 10.1002/prca.200900015.

PMID:
21137010
2.

Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods.

Johnston O, Cassidy H, O'Connell S, O'Riordan A, Gallagher W, Maguire PB, Wynne K, Cagney G, Ryan MP, Conlon PJ, McMorrow T.

Proteomics Clin Appl. 2011 Aug;5(7-8):422-31. doi: 10.1002/prca.201000160. Epub 2011 Jul 13.

PMID:
21751411
3.

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.

Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH.

Lab Invest. 2007 Feb;87(2):161-72.

4.

Time course proteomic profile of rat acute myocardial infarction by SELDI-TOF MS analysis.

Zhang G, Zhou B, Zheng Y, Feng K, Rao L, Zhang J, Xin J, Zhang B, Zhang L.

Int J Cardiol. 2009 Jan 9;131(2):225-33. doi: 10.1016/j.ijcard.2007.10.021. Epub 2008 Jan 3.

PMID:
18180059
5.

Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).

O'Gorman D, Howard JC, Varallo VM, Cadieux P, Bowley E, McLean K, Pak BJ, Gan BS.

Clin Invest Med. 2006 Jun;29(3):136-45.

PMID:
17058431
6.
7.

Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.

Wang JX, Zhang B, Yu JK, Liu J, Yang MQ, Zheng S.

Chin Med J (Engl). 2005 Aug 5;118(15):1278-84.

PMID:
16117882
8.

Renal outcome 25 years after donor nephrectomy.

Goldfarb DA, Matin SF, Braun WE, Schreiber MJ, Mastroianni B, Papajcik D, Rolin HA, Flechner S, Goormastic M, Novick AC.

J Urol. 2001 Dec;166(6):2043-7.

PMID:
11696703
9.

Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots.

Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, Field E, Schatz CR, Estock MA, Ahmed N, Anderson NG, Steiner S.

Proteomics. 2004 Apr;4(4):1159-74.

PMID:
15048996
10.

Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy.

Cho A, Lee JE, Kwon GY, Huh W, Lee HM, Kim YG, Kim DJ, Oh HY, Choi HY.

Nephrol Dial Transplant. 2011 Nov;26(11):3496-501. doi: 10.1093/ndt/gfr094. Epub 2011 Mar 15.

PMID:
21406544
11.

[Application of SELDI-TOF serum proteome profiling in cervical squamous cell carcinoma].

Xia T, Zheng ZG, Gao Y, Mou HZ, Xu SH, Zhang P, Zhu JQ.

Ai Zheng. 2008 Mar;27(3):279-82. Chinese.

PMID:
18334117
12.

Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.

Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA, Partin AW, Veltri RW.

Prostate. 2004 Sep 1;60(4):325-31.

PMID:
15264244
13.

Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis.

Cadieux PA, Beiko DT, Watterson JD, Burton JP, Howard JC, Knudsen BE, Gan BS, McCormick JK, Chambers AF, Denstedt JD, Reid G.

J Clin Lab Anal. 2004;18(3):170-5.

PMID:
15103681
14.
15.
16.

Long-term follow-up after partial removal of a solitary kidney.

Novick AC, Gephardt G, Guz B, Steinmuller D, Tubbs RR.

N Engl J Med. 1991 Oct 10;325(15):1058-62.

17.

Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer.

Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N, Young-Lae C, Ho-Sun C, Heung-Jae J, Chong-Kook K, Young-Wan K, Byoung-Don H, Hyun-Sun J.

Cancer Sci. 2005 Mar;96(3):197-201.

18.

Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.

Xu G, Xiang CQ, Lu Y, Kang XN, Liao P, Ding Q, Zhang YF.

Cancer Lett. 2009 Sep 18;282(2):205-13. doi: 10.1016/j.canlet.2009.03.017. Epub 2009 Apr 11.

PMID:
19362769
19.

Nephron-sparing surgery for renal cell carcinoma in the solitary kidney.

Berdjis N, Hakenberg OW, Novotny V, Manseck A, Oehlschläger S, Wirth MP.

Scand J Urol Nephrol. 2007;41(1):10-3.

PMID:
17366096
20.

Characterization of discriminatory urinary proteomic biomarkers for severe preeclampsia using SELDI-TOF mass spectrometry.

Lee SM, Park JS, Norwitz ER, Kim SM, Kim BJ, Park CW, Jun JK, Syn HC.

J Perinat Med. 2011 Jul;39(4):391-6. doi: 10.1515/JPM.2011.028. Epub 2011 May 10.

PMID:
21557676

Supplemental Content

Support Center